Pasar al contenido principal

DECIPHERING THE ROLE OF UBIQUITIN-LIKE MODIFIERS IN THE ETIOLOGY OF RARE DISEASES

PID2023-147399NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

  • El Motiam, Ahmed
  • Bouzaher, Yanis H
  • Chen, Haifen
  • Seoane, Rocío
  • Vidal, Santiago
  • Blanquer, María
  • Tolosa, Rocío M
  • Rodríguez-Lemus, Beatriz
  • Herrera-Gavilán, José A
  • Vidal, Anxo
  • Palmero, Ignacio
  • Rodríguez, Manuel S.
  • Sutherland, James D
  • Barrio, Rosa
  • Xirodimas, Dimitris
  • Collado, Manuel
  • Bremner, Rod
  • Rivas, Carmen
p14ARF is a lysine-less tumor suppressor that enhances SUMOylation of its interactors. Although p14ARF is known to interact with the E2 SUMO conjugating enzyme UBC9, the link between ARF and SUMOylation is poorly understood and the potential impact of SUMOylation on p14ARF is unknown. Here we show that SUMO2 conjugates to the N-terminus of p14ARF and stabilizes it. Either depleting UBC9 or pharmacologically inhibiting SUMOylation, induces p14ARF degradation. In contrast, blocking ubiquitination or NEDDylation, with TAK-243 or MLN4924/Pevonedistat respectively, increases p14ARF SUMOylation and restores p14ARF levels when SUMOylation is blocked. Treatment with MLN4924 also causes p14ARF-dependent mRNA upregulation of the SUMOylation components SUMO1, SUMO2, and UBC9, globally augmenting SUMOylation. Finally, p14ARF contributes to MLN4924-driven cytotoxicity of prostate cancer cells. Our results provide evidence that, despite lacking lysine, p14ARF is SUMOylated and this modification is critical to counter ubiquitin driven degradation and establishes a new link between inhibition of NEDDylation and SUMOylation., Funding at the laboratory of CR is provided by Ministry of Science, Innovation and Universities and FEDER (PID2021-126510NB-I00), and Xunta de Galicia/ FEDER “Una manera de hacer Europa” (ED431G 2023/10). MB is a predoctoral fellow funded by Banco Santander and University of Santiago de Compostela. RMT is a predoctoral fellow funded by Instituto de Investigación Sanitaria de Santiago de Compostela. BRL is a predoctoral fellow funded by Asociación Española Contra el Cáncer (AECC). JAHG is funded by FPU grant from Ministry of Science and Innovation (MCIN), Spain (FPU23/00271). CR, MSR, JDC, DX, and RB acknowledge COST Action ProteoCure CA20113. RB and JDS acknowledge MCIN/AEI/10.13039/501100011033 (projects PID2023-147399NB-I00 and PID2020-114178GB-I00). IP lab is funded by PID2021-122600OB-I0., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Pujana-Vaquerizo, Mikel
  • Martínez-Laosa, Belén
  • Ponce-Rodríguez, María
  • García-Longarte, Saioa
  • Mendizabal, Isabel
  • Gimeno, Ana
  • Rogalska, Malgorzata
  • Tan, Joycelyn
  • Cabrera, Diana
  • van Liempd, Sebastiaan
  • Ximenez-Embun, Pilar
  • Espinosa, Sergio
  • Fagoaga-Eugui, Maider
  • Peccati, Francesca
  • Zakrzewski, Maciej
  • Astobiza, Ianire
  • Arana-Castañares, Mikel
  • Cherkaoui, Sarah
  • Sendino, Maria
  • Martín-Barros, Inés
  • Ercilla, Amaia
  • Bozal-Basterra, Laura
  • Carlevaris, Onintza
  • Arruabarrena-Aristorena, Amaia
  • Pérez-Andrés, Encarnación
  • Santamaria-Zamorano, Telmo
  • Ferrer-Bonsoms, Juan A.
  • Carazo, Fernando
  • Ciesla, Maciej
  • Lobato, Cesar
  • Seoane, Joan
  • Martín-Martín, Natalia
  • Barrio, Rosa
  • Sutherland, James D.
  • Aransay, Ana M.
  • Falcón-Pérez, Juan Manuel
  • Martínez-Pastor, Barbara
  • Rubio, Angel
  • Blanco, Francisco J.
  • Hogarty, Michael D.
  • Morscher, Raphael J.
  • Berra, Edurne
  • Serwa, Remigiusz A.
  • Jiménez-Barbero, Jesús
  • Jiménez-Osés, Gonzalo
  • Efeyan, Alejo
  • Finley, Lydia
  • Lizcano, Jose M.
  • Muñoz, Javier
  • Valcarcel, Juan
  • Carracedo, Arkaitz
40 páginas, figuras y material suplementario., Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).